The American Association for Cancer Research’s annual conference kicks off Friday as more than 20,000 attendees descend on San Diego. Analysts and researchers who spoke with BioSpace said they’re looking forward to early scientific data, and antibody-drug conjugates (ADCs) will be a key focus.
Philips announced the main terms of an agreement it reached in January with the U.S. government on its new sleep apnea machines, which has already cost the company over 360 million euros in the fourth quarter of 2023, sending its shares up almost 3% on Wednesday.
Moderna shares rose 8% in morning trade on Tuesday after the company’s individualized cancer vaccine developed with Merck showed positive response in an early-stage trial in patients with a type of head and neck cancer.
Two biotechs, Nvelop Therapeutics and Seaport Therapeutics, emerged from stealth Tuesday with $100 million in financing as they look to target the neuropsychiatric and gene editing spaces, respectively.
Novartis is to cut up to 680 jobs in its development organization, which helps bring its drugs to market, the Swiss pharmaceuticals company said on Tuesday.
Despite hitting the market more than a year ago with steep discounts, biosimilars for AbbVie’s blockbuster arthritis treatment Humira (adalimumab) have managed to take only 4% of the market share away from the branded reference product, according to the latest quarterly report from Samsung Bioepis.
Merck has bought biotech startup Abceutics in a bid to develop safer antibody-drug conjugates and minimize their off-target effects on healthy cells, according to a Friday announcement from the University at Buffalo, whose laboratory created the spin-off company.
Bristol Myers Squibb on Saturday unveiled interim data from the Phase III open-label EMERGENT-4 study, showing that the investigational antipsychotic KarXT (xanomeline and trospium) can elicit significant and sustained symptom improvement in patients with schizophrenia.
Supernus Pharmaceuticals said on Monday the U.S. FDA declined to approve its drug-device combination to treat movement-related symptoms of Parkinson’s disease, sending its shares down 9% in early trade.
The American College of Cardiology’s 73rd Annual Scientific Session & Expo (ACC24) took place over the weekend in Atlanta, spotlighting the latest and most impactful innovations in the field of cardiovascular care.